|
|
|
|
SNM warns patients about imaging test delays due to worldwide Mo-99 shortage
Cancer Breaking News EUREKALERT Contact: Amy Shaw 703-652-6773 WHO: Leaders of SNM Michael M.Graham, Ph. D., M.D., president, SNM Robert W. Atcher, Ph. D., M.B.A., past president, SNM; chair, SNM Medical Isotope Task Force Jeffrey P. Norenberg, Pharm...
|
|
|
ACC Feature: New F18-labeled PET perfusion tracer trumps technetium
ATLANTAA novel F18-labeled PET perfusion imaging agent has shown higher specificity for detecting right coronary artery disease (CAD) compared to SPECT imaging with technetium-99m (Tc-99m).In addition, the PET agent detected more severe and extensive...
|
|
|
SNM cautions medical community about severe isotope shortage
The SNM has cautioned that the period between March 21 and April 11 would be the time when the medical community would face "- More - DRAXIMAGE LAUNCHES SESTAMIBI We are proud to announce that DRAXIMAGE's Kit for the Preparation of Technetium Tc 99m...
|
|
|
SNM Warns Patients About Imaging Test Delays Due To Worldwide Mo-99 Shortage
Main Category: Also Included In: / Oncology / Cardiology Article Date: 19 Mar 2010 WHO: Leaders of SNM Michael M.Graham, Ph. D., M.D., president, SNM Robert W. Atcher, Ph. D., M.B.A., past president, chair, SNM Medical Isotope Task Force Jeffrey P.
|
|
|
Global halt on Molybdenum-99 production: Discussion of implications
Michael M.Graham, Ph.D., M.D., president, SNM Robert W. Atcher, Ph.D., M.B.A., past president, SNM; chair, SNM Medical Isotope Task Force Jeffrey P. Norenberg, Pharm.D., M.S., SNM director-at-large; chair, SNM Commission on Radiopharmaceuticals; member,...
|
|
|
Study: New PET tracer aids in heart failure prognosis
For heart failure prognosis, the LMI1195 PET tracer provides better images of the sympathetic nervous system compared with SP- More - DRAXIMAGE LAUNCHES SESTAMIBI We are proud to announce that DRAXIMAGE's Kit for the Preparation of Technetium Tc 99m...
|
|
|
F18 PET Diagnoses Coronary Artery Disease Better than SPECT
Preliminary results from the single-center study suggest that compared to SPECT myocardial perfusion imaging (MPI), flurpiridaz F18 PET MPI has a higher diagnostic specificity for detecting right coronary artery disease and a higher accuracy for evaluating the...
|
|
|
March 3rd, 2010 Atreus Pharma scores $6M to develop arthritis-detecting product
Atreus which is not to be confused with Internet protocol-based technology maker Atreus Systems said Wednesday that Frances Advanced Accelerator Applications will be making a multi-stage investment to help the local company with its development of a new type of...
|
|
|
Lantheus Medical Imaging, Inc. Presents Preliminary Phase 2 Data With Flurpiridaz F 18 (BMS747158), a Novel PET Cardiac Imaging Agent, at the American
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--., a worldwide leader in diagnostic imaging, today announced preliminary data on flurpiridaz F 18 (formerly known as BMS747158), its novel compound in development as a Positron Emission Tomography (PET) myocardial...
|
|
|
F18-PET Diagnoses Coronary Artery Disease Better than SPECT
- Preliminary results from the single-center study suggest that compared to SPECT MPI, flurpiridaz F 18 PET MPI has a higher diagnostic specificity for detecting right coronary artery disease and a higher accuracy for evaluating the extent of stress-induced...
|
|
|
Lantheus Medical Imaging, Inc. Presents Preliminary Phase 2 Data With Flurpiridaz F 18 (BMS747158), a Novel PE
Single-Center Data Suggest Significantly Improved Diagnostic Accuracy and Specificity With New PET Agent Versus SPECT NORTH BILLERICA, Mass.(BUSINESS WIRE) Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced preliminary...
|
|
|
Lantheus Medical Imaging, Inc. Presents Preliminary Phase 2 Data With Flurpiridaz F 18 (BMS747158), a Novel PET Cardiac Imaging Agent, at the American College Of Cardiology 59th Annual Scientific Session
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced preliminary data on flurpiridaz F 18 (formerly known as BMS747158), its novel compound in development as a Positron Emission Tomography (PET) myocardial perfusion imaging ...
|
|
|
Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced preliminary data on flurpiridaz F 18 (formerly known as BMS747158), its novel compound in development as a Positron Emission Tomography (PET) myocardial perfusion imaging ...
|
|
|
Lantheus Medical Imaging, Inc. Presents Preliminary Phase 2 Data With Flurpiridaz F 18 (BMS747158), a Novel PET Cardiac Imaging Agent, at the American College Of Cardiology 59th Annual Scientific Sess
Companies mentioned in this article: Lantheus Medical Imaging, Inc.NORTH BILLERICA, Mass. -- (BUSINESS WIRE) -- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced preliminary data on flurpiridaz F 18 (formerly known...
|
|
|
High-Dose Donepezil Slows Symptom Progression in Advanced Alzheimer's Disease: Presented at ADI
my personal edition> alzheimer's > news E-Mail this DGDispatch to a colleague DGDispatch THESSALONIKI, Greece -- March 13, 2010 -- According to the data presented here on March 11 at the 25th Conference of Alzheimer's Disease International (ADI),...
|
|
|
Covidien Looks to Reactor in Poland to Ease Global Shortage of Isotope
The global shortage of technetium 99m (Tc-99m), the most widely used diagnostic Covidien Looks to Reactor in Poland to Ease Global Shortage of Isotope.
|
|
|
U.S., Canadian health officials OK Polish isotopes
Policy Last Updated: 2010-03-11 14:00:38 -0400 (Reuters Health) * Approvals should help ease medical isotope shortage * Scarce material should be available later this month CHICAGO (Reuters) - U.S.and Canadian health officials have approved the use of the...
|
|
|
Covidien to use FDA, Health Canada approved Mo 99 from Maria for manufacturing Tc 99m generators
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S.Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor (Maria) in Poland as a site to irradiate highly...
|
|
|
U.S. FDA and Health Canada Approve Use of Molybdenum 99 From Maria Reactor
Let the jobs come to you!Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S! Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor (Maria) in Poland as a...
|
|
|
U.S. FDA and Health Canada Approve Use of Molybdenum 99 From Maria Reactor
LOUIS-- (BUSINESS WIRE) -- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S.Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor (Maria) in Poland as a...
|
|
|
FDA Approves Alternate Source for Widely Used Diagnostic
To help ease the global shortage of technetium 99m (Tc-99m), the most widely use FDA Approves Alternate Source for Widely Used Diagnostic.
|
|
|
Advanced Accelerator Applications invests $6 million for Annexin research
Advanced Accelerator Applications has invested approximately $6 million in Atreus Pharmaceuticals which will be used to expand Atreus research in molecular imaging based on Annexin V.Atreus, headquartered in Ottawa, develops in-vivo radiopharmaceutical...
|
|
|
FDA and Health Canada approve use of Mo-99 from Polish reactor
The U.S.Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor in Poland as a site to irradiate highly-enriched uranium targets for molybdenum-99 (Mo-99) production, according to Covidien. Covidien said it...
|
|
|
FDA and Health Canada approve use of Mo-99 from Polands reactor
The U.S.Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor in Poland as a site to irradiate highly-enriched uranium targets for molybdenum-99 (Mo-99) production, according to Covidien. Covidien said it...
|
|
|
U.S. FDA and Health Canada Approve Use of Molybdenum 99 From Maria Reactor
LOUIS - (BUSINESS WIRE) - Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S.Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor (Maria) in Poland as a...
|
